Post Profile






PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA

(University of Texas M. D. Anderson Cancer Center) In a randomized, Phase III trial led by researchers at the University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
read more

share

Related Posts


PARP inhibitor may be effective against some TNBC lacking BRCA mutations

Health : EurekAlert: Health

(American Association for Cancer Research) The investigational PARP inhibitor talazoparib caused regression of patient-derived xenografts (PDXs) of triple-negative breast cancers (TNBC) that had BRCA mutations and also those that di...

Frontline PARP inhibitor shrinks tumors in BRCA-positive breast patients

Diseases & Conditions / Cancer : EurekAlert: Cancer

(University of Texas M. D. Anderson Cancer Center) All 13 newly diagnosed breast cancer patients with BRCA mutations had their tumors shrink significantly when treated with a PARP inhibitor ahead of frontline presurgical chemotherap...

MD Anderson-led study finds ribociclib improves progression-free survival for women with metastatic breast cancer

Health : EurekAlert: Health

(University of Texas M. D. Anderson Cancer Center) In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, ribociclib, in combination with the aromatase inhibitor letrozole, dramatic...

Ribociclib Improves Progression-Free Survival for Women with Metastatic Breast Cancer

Health : Newswise Medical News

In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, ribociclib, in combination with the aromatase inhibitor letrozole, dramatically improved progression-free survival (PFS) of po...

PARP Inhibitor Improves Progression-Free Survival in Patients with Advanced Breast Cancers and BRCA Mutations

Health : Newswise Medical News

In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available c...

Comments


Copyright © 2016 Regator, LLC